Market Place
Sourcing Support
Robbins Geller: IBRX Investors Can Lead Class Action Suit
10 Apr 2026 //
PHARMIWEB
Immunitybio Announces NCCN Clinical Practice Guidelines
17 Mar 2026 //
BUSSINESSWIRE
Immunitybio To Review FY 2025 Financial Results On March 3, 2026
27 Feb 2026 //
PHARMIWEB
ImmunityBio Q2 Earnings Show 60% Revenue Rise, $43M YTD Sales
05 Aug 2025 //
BUSINESSWIRE
Global Expansion Plans Set For Anktiva Cancer Treatment
15 Jan 2025 //
BUSINESSWIRE
ImmunityBio Updates Progress On FDA Regulatory Submissions
15 Jan 2025 //
BUSINESSWIRE
ImmunityBio Reports Third-Quarter 2024 Financial Results
12 Nov 2024 //
BUSINESSWIRE
Cash-crunched ImmunityBio, on heels of FDA nod for Anktiva, lays off staffers
05 Sep 2024 //
FIERCE PHARMA
ImmunityBio to Lay Off 16, Will Likely Need Additional Capital
04 Sep 2024 //
BIOSPACE
ImmunityBio`s ANKTIVA Covered By Plans Representing 100M+ Lives
12 Aug 2024 //
BUSINESSWIRE
ImmunityBio Studies ANKTIVA® With AdHER2DC For Endometrial Cancer
06 Aug 2024 //
BUSINESSWIRE
ImmunityBio`s ANKTIVA Gains Insurance Coverage, First Doses Administered
20 Jun 2024 //
BUSINESSWIRE
ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
07 Jun 2024 //
BUSINESSWIRE
LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License
03 Jun 2024 //
BUSINESSWIRE
UroToday Podcast Explores ANKTIVA Triangle Offense With Dr Soon-Shiong
17 May 2024 //
BUSINESSWIRE
ImmunityBio Completes ANKTIVA Manufacturing For 170K Doses
07 May 2024 //
BUSINESSWIRE
ImmunityBio, Serum Institute In BCG Global Supply Arrangement
02 May 2024 //
BUSINESSWIRE
ImmunityBio`s Soon-Shiong To Discuss ANKTIVA® At AUA Conference
30 Apr 2024 //
BUSINESSWIRE
ImmunityBio`s Anktiva+CPI Shows Survival Benefit in NSCLC
25 Apr 2024 //
BUSINESSWIRE
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
16 Nov 2023 //
BUSINESSWIRE
First Data for Immunity’s Cytokine-Enriched NK Cells in Small Cell Lung Cancer
07 Nov 2023 //
BUSINESSWIRE
Second layoff wave hits ImmunityBio in less than a year
22 Sep 2023 //
FIERCE BIOTECH
ImmunityBio Announces $470 Million Equity and Debt Financing From Dr. Patrick
11 Sep 2023 //
BUSINESSWIRE
ImmunityBio Names Enrique Diloné as Chief Technology Officer
03 Aug 2023 //
BUSINESSWIRE
ImmunityBio Announces Execution of $40M Equity Financing with Investors
20 Jul 2023 //
BUSINESSWIRE
ImmunityBio to Participate in the Jefferies Global Healthcare Conference
22 May 2023 //
BUSINESSWIRE
ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar?
08 May 2023 //
FINANCE YAHOO
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong
24 Apr 2023 //
BUSINESSWIRE
ImmunityBio Announces Execution of $50M Equity Financing with Investors
15 Feb 2023 //
BUSINESSWIRE
ImmunityBio Announces $157 Million Financing From Investor
12 Dec 2022 //
BUSINESSWIRE
ImmunityBio looks to pull in $157M from Patrick Soon-Shiong and investor
12 Dec 2022 //
ENDPTS
Arbitrator awards $157M to Soon-Shiong`s ImmunityBio in dispute with Sorrento
05 Dec 2022 //
ENDPTS
ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference
17 Nov 2022 //
BUSINESSWIRE
ImmunityBio to Participate in the Jefferies London Healthcare Conference
27 Oct 2022 //
BUSINESSWIRE
ImmunityBio, aiming to hire 300 in 30 months, lays off staff
10 Oct 2022 //
FIERCEBIOTECH
ImmunityBio Announces FDA Acceptance of BLA for N-803
28 Jul 2022 //
BUSINESSWIRE
ImmunityBio Announces QUILT Trial Results for Cancers at the 2022 ASCO
06 Jun 2022 //
BUSINESSWIRE
ImmunityBio Submits BLA for N-803 Plus BCG for Patients in Bladder Cancer
23 May 2022 //
BUSINESSWIRE
ImmunityBio Announces First Participants Have Been in Lung-MAP Trial Studying
25 Apr 2022 //
BUSINESSWIRE
ImmunityBio Provides Updated Status of BLA for VesAnktiva Plus BCG
01 Apr 2022 //
BUSINESSWIRE
Memory Cytokine-Enhanced Natural Killer Cells Show Promising Results in Leukemia
02 Mar 2022 //
BUSINESSWIRE
ImmunityBio Acquires Athenex’s Interest in Advanced Biotech Mfg Facility
15 Feb 2022 //
BUSINESSWIRE
ImmunityBio Shows Promising Clinical Study Results for ‘Kick and Kill’ HIV Cure
31 Jan 2022 //
BUSINESSWIRE
ImmunityBio Presents Interim Data from Phase 2 QUILT 88 Trial
20 Jan 2022 //
TRIALSITENEWS
ImmunityBio Shows Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO
18 Jan 2022 //
BUSINESSWIRE
ImmunityBio Expands Manufacturing Capacity with State-of-Art Manufacturing Plant
12 Jan 2022 //
BUSINESSWIRE
Amyris and ImmunityBio Complete JV for Next Gen COVID-19 RNA Vaccine
03 Jan 2022 //
PRESS RELEASE
CytRx Highlights ImmunityBio`s Use of Aldoxorubicin in Various Forms of Cancer
21 Dec 2021 //
BUSINESSWIRE
ImmunityBio Completeds $470M Post-merger Financing to Fund Trials and Filings
20 Dec 2021 //
BUSINESSWIRE
Sciwind gets licensing deal with Sanofi for metabolic disease candidates
30 Nov 2021 //
ENDPTS
ImmunityBio to Accelerate Use of “Mix-&-Match” Technologies in COVID-19 Vaccines
18 Nov 2021 //
BUSINESSWIRE
ImmunityBio Meets Primary Endpoint in Second Indication
19 Oct 2021 //
BUSINESSWIRE
ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine
13 Oct 2021 //
BUSINESSWIRE
NCI to combine ImmunityBio’s N-803 with Keytruda in Lung-MAP Trial
04 Oct 2021 //
BUSINESSWIRE
NCI to combine ImmunityBio’s N-803 with Keytruda in Lung-MAP Trial
04 Oct 2021 //
BUSINESSWIRE
ImmunityBio Announces +ve Responses in BCG Unresponsive Bladder Cancer Patients
13 Sep 2021 //
BUSINESSWIRE
ImmunityBio Builds Team with the Appointment of Seasoned Marketing Executives
07 Sep 2021 //
BUSINESSWIRE
ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results
01 Sep 2021 //
BUSINESSWIRE
ImmunityBio’s Novel Immunotherapy NANT Cancer Vaccine
27 Jul 2021 //
PR NEWSWIRE
ImmunityBio to Proceed with Phase 1/2/3 of their COVID Vaccine
14 Jul 2021 //
BUSINESS WIRE
